Treatment News : Strong Link Between Taking PrEP Daily and Preventing HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 6, 2014

Strong Link Between Taking PrEP Daily and Preventing HIV

Adhering to the daily dosing schedule of pre-exposure prophylaxis is fundamental to PrEP’s success at preventing the acquisition of HIV, aidsmap reports. Publishing their findings in the Journal of Acquired Immune Deficiency Syndromes, investigators in the Partners PrEP study drew a cohort from a pool of 4,747 men and women in Kenya and Uganda who had a partner living with HIV and who were given either Truvada, which contains tenofovir and emtricitabine, or just tenofovir, as PrEP. The cohort included 29 people who contracted HIV during the study and 196 randomly selected participants who remained HIV negative and who served as controls.

Seventy-one percent of the controls had tenofovir levels that indicated they were taking PrEP daily, compared with just 32 percent of those who seroconverted. Counts of the pills the participants took indicated that 96 percent of the controls adhered at a rate greater than 80 percent, compared with 65 percent of the seroconverters. Five out of 29 (17 percent) of those who contracted HIV appeared to take PrEP consistently.

The researchers estimated that daily use of Truvada reduced the risk of contracting HIV by 91 percent, and that tenofovir on its own reduced the risk by 89 percent.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, pre-exposure prophylaxis, PrEP, Truvada, tenofovir, emtricitabine, adherence.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.